best casino sites usa
My Date with Rural China----VOC.com.cn Unveils Season Two of I Am in Rural ChinaSmith & Wesson: Fiscal Q2 Earnings SnapshotTom Phillips, Hamilton Pullman Hotel and Te Kūiti baby death: The big stories of June 2024
Near Infrared Imaging Market to Reach USD3.2 Billion by 2034 with a 3.9% of CAGR 12-24-2024 06:12 PM CET | Health & Medicine Press release from: Future Market Insights Near Infrared Imaging Market The global near infrared (NIR) imaging market is set to experience steady growth over the coming decade, with its valuation expected to rise from USD 2.2 billion in 2024 to USD 3.2 billion by 2034. This growth trajectory represents a compound annual growth rate (CAGR) of 3.9% over the forecast period. The market's expansion reflects the increasing adoption of NIR imaging technology in medical diagnostics, surgical procedures, and preclinical research. The progression of the market from USD2.1 million in 2022 to a projected USD2.2 billion in 2024 highlights the significant investment and demand for advanced imaging solutions. Near infrared imaging, known for its ability to provide clear, real-time images of tissues, blood vessels, and lymph nodes, has become an indispensable tool in cancer surgery, vascular imaging, and tissue analysis. The technology's non-invasive nature, coupled with its precision, is driving its adoption in clinical and research settings. Request a Sample of this Report Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-18251 As healthcare providers seek to enhance surgical precision and reduce complications, NIR imaging is gaining momentum as a vital component of image-guided surgery. The rising prevalence of cancer and the growing need for minimally invasive procedures are further propelling demand. Key stakeholders, including hospitals, research institutions, and biotech firms, are investing heavily in the development of next-generation NIR imaging systems. Key Takeaways The global near infrared imaging market is projected to grow from USD2.2 billion in 2024 to USD3.2 billion by 2034, with a CAGR of 3.9%. The market's growth from USD2.1 million in 2022 to USD2.2 billion in 2024 underscores rising demand for NIR imaging technology. Near infrared imaging is increasingly being adopted for cancer surgery, vascular imaging, and tissue analysis due to its real-time, non-invasive imaging capabilities. Rising demand for minimally invasive procedures and growing healthcare investments are driving the development of next-generation NIR imaging systems. As advancements in medical imaging technology continue, near infrared imaging is set to play an essential role in improving diagnostic accuracy, surgical outcomes, and patient care. This growing market reflects the shift toward precision medicine and the development of cutting-edge imaging tools in modern healthcare. Market Drivers Advancements in Imaging Technology: Continuous improvements in near infrared imaging technology are enhancing diagnostic capabilities, making it a preferred choice in various medical applications. Increasing Demand for Non-Invasive Procedures: The non-invasive nature of near infrared imaging techniques is driving their adoption in clinical settings, particularly for surgical guidance and diagnostics. Growing Prevalence of Chronic Diseases: The rising incidence of conditions such as cancer and cardiovascular diseases is boosting the demand for effective imaging solutions, including near infrared technologies. Rising Awareness and Acceptance: Increased awareness among healthcare professionals and patients about the benefits of near infrared imaging is contributing to market growth. Government Initiatives and Funding: Supportive government policies and funding for medical research are facilitating advancements in near infrared imaging technologies. Regional Insights North America: Expected to dominate the market due to advanced healthcare infrastructure and high rates of chronic diseases. Asia-Pacific: Anticipated to exhibit significant growth driven by increasing healthcare expenditures and a growing population. Challenges High Costs of Equipment: The cost associated with advanced near infrared imaging systems may limit accessibility for some healthcare facilities. Regulatory Hurdles: Navigating regulatory requirements for new imaging technologies can pose challenges for manufacturers. Competitive Landscape in the Near Infrared Imaging Market The key players are increasingly leveraging the benefits of collaborations. Manufacturers are taking advantage of partnerships with hospitals, mergers with other manufacturers in the market, acquisitions, and more collaborative strategies. The pharmacy automation market does not feature highly dominant manufacturers. Instead, the market is fragmented, with several key players enjoying their share. Manufacturers are also receiving increasing approvals from several governments to enhance their pharmaceutical infrastructure for medical purposes. Recent Developments in the Near Infrared Imaging Market In 2023, Quest Medical Imaging launched its NIR-II Fluorescence Imaging System, providing high-resolution imaging in the second near-infrared (NIR-II) window. This system offers deeper tissue penetration and reduced scattering compared to traditional NIR imaging systems. In 2022, Leica Microsystems launched its NIR Fluorescence Imaging System, designed for use in both clinical and research settings. The system offers high-resolution imaging and compatibility with a wide range of NIR dyes. In 2023, Medtronic (Visionsense) received FDA approval for its NIR Fluorescence Imaging System, designed for use in minimally invasive spine surgery. The system aids in visualizing nerve structures and blood vessels. In 2022, Stryker received FDA clearance for its SureView NIR Imaging System, designed for use in minimally invasive surgical procedures. The system incorporates NIR technology to enhance visualization of blood flow and perfusion during surgery. Near Infrared Imaging Market Key Players Quest Medical Imaging B.V. Stryker KARL STORZ SE & Co. KG Olympus Hamamatsu Photonics K.K. Mizuho Medical Co, Ltd. Shimadzu Corporation Leica Microsystems Medtronic PerkinElmer, Inc. Carl Zeiss Meditec Fluoptics Key Segments By Product Type: Devices Near-infrared Fluorescence Imaging Systems Near-infrared Fluorescence & Bioluminescence Imaging Systems Reagents Indocyanine Green (ICG) Other Reagents By Application: Preclinical Imaging Cancer Surgeries Gastrointestinal Surgeries Cardiovascular Surgeries Plastic/Reconstructive Surgeries Other Applications By End Use: Hospitals & Clinics Pharmaceutical & Biotechnology Companies Research Laboratories By Region: North America Latin America Europe South Asia East Asia Oceania Middle East and Africa (MEA) Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain: Direct-to-Consumer Genetic Testing Market - https://www.futuremarketinsights.com/reports/direct-to-consumer-genetic-testing-market Biotherapeutics Virus removal filters Market - https://www.futuremarketinsights.com/reports/biotherapeutics-virus-removal-filters-market Oncology Information Systems Market - https://www.futuremarketinsights.com/reports/oncology-information-systems-market About Future Market Insights (FMI) Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Contact Us: Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-347-918-3531 For Sales Enquiries: sales@futuremarketinsights.com Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs | YouTube This release was published on openPR.Telcos' Investment Recovery In Doubt As Tariff Hike Backfires, Price War With Satcom Services Looms In 2025
Chicago Bears fans have experience with bad seasons. It’s been the norm for the last 12 years since they fired coach Lovie Smith after a 10-6 campaign in 2012. But what they have experienced in 2024 has been very disappointing, as there was a lot of hope after the selection of quarterback Caleb Williams as the number 1 pick in the Draft, a couple of good offensive signings, and a defense that seemed to be above average. PUBLICIDAD With a 6-3 defeat against the Seattle Seahawks, in the worst game of the entire 2024 NFL season, the Bears suffered their tenth consecutive loss (matching the worst record in a season in history) and worsened their record to 4-12. Far from what fans had dreamed of in the preseason. PUBLICIDAD Therefore, with anger and disappointment at the surface, in the last minutes of Thursday night's game at Soldier Field in Chicago, a unique shout was heard loud and clear: "Sell the team! Sell the team! Sell the team!" The chant was directed towards the McCaskey family, who have been controlling the team for 103 years. The team was bought by George Halas and after his death, it remained in the hands of Virginia Halas McCaskey, who is now 101 years old, and she passed the management to her son George McCaskey. What are the profound changes that the Chicago Bears must make? The Bears have one game left this season, which will surely end in defeat when they visit their arch-rivals, the Packers, in Green Bay . If this scenario plays out, it will be the first time in franchise history that the team reaches 11 consecutive losses in a season. Chicago's losing streak began on October 27 in Washington, when opposing quarterback Jayden Daniels converted a "Hail Mary" into a touchdown on the last play of the game. Fan videos showed an embarrassing image when cornerback Tyrique Stevenson was seen mocking the opposing fans instead of defending against the last pass. The Bears never recovered from that moment and the locker room was definitively fractured: in an unprecedented move during the regular season in Chicago, the offensive coordinator (Shane Waldron) and the head coach (Matt Eberflus) were fired. Therefore, after the meeting in Green Bay, the Bears will focus on making profound changes, which should also include general manager Ryan Poles, responsible for several of the team's poor decisions. The new coach (Ben Johnson, current offensive coordinator of the Detroit Lions, emerges as the top candidate) will need to focus on rebuilding the porous offensive line of Chicago, strengthening a defense that is not as good as believed, and changing the defeatist mentality in the locker room. Can the McCaskeys sell the Chicago Bears? NFL teams are rarely sold, as due to the league's millionaire contracts, they always generate profits. The last team to change ownership was the Washington Commanders, when the NFL forced owner Dan Snyder to sell after a series of investigations, including one by the House of Representatives, reported a toxic work environment in the organization, with allegations of workplace abuse and sexual harassment. Snyder sold the team for $6 billion to a group led by Josh Harris (owner of the NBA's 76ers). The Bears should cost much more, since Chicago is the third largest market in the United States. Forbes valued the Illinois team at 6.4 billion dollars. Nevertheless, to date, there is no news that the McCaskey family wants to get rid of the property, although they are interested in a business partner to finance the new stadium project. A few days ago, the possibility of Jeff Bezos as a potential buyer appeared on social media, but it all originated from a post by a betting house that mentioned the Amazon owner as the main candidate to take control of the Chicago Bears.Our Lady of the Lake to take on Clarkston Everest for D4 state volleyball title
In the aftermath of the killing of United Healthcare CEO Brian Thompson , while Thompson’s colleagues grieve and politicians decry his murder, some online discussion has shown little sympathy for Thompson or the industry he represented. Instead, social media has been in engulfed in expressions of anger at many Americans’ dire experiences at the hands of health insurance companies and outrage at the large profits that they generate. That belies the shock also generated by the brutality of Thompson’s death. The killing appeared premeditated and calculated. A gunman dressed in black waited for Thompson outside the midtown Manhattan Hilton where he was scheduled to speak at an investor’s meeting, approached him from behind with a handgun fitted with a silencer, and shot and killed the executive, according to police. He fled on an ebike into Central Park. A manhunt is ongoing. The motive is unknown. Andrew Witty, CEO of the parent company, UnitedHealth Group, called the attack “a terrible tragedy” in a message sent to company employees and shared with the Guardian. “Our hearts are with his family, especially his mom, his wife Paulie, his brother and his two boys, who lost a father today,” Witty said. Amy Klobuchar, a Democratic US Senator from Minnesota, described the killing as “a horrifying and shocking act of violence”. But in contrast, one commenter on CNN’s Instagram post about Thompson’s death wrote: “Can’t find the room to care over my daughter’s $60,000 cancer treatment. Thoughts and prayers.” Another said: “An innocent victim was gunned down in cold blood. Have a heart regardless of your health insurance.” Vacillating between the condemnation of violence and dark humor, celebratory memes and outright violent rhetoric, comments on social media highlight the deep and often unpleasant connection Americans have with their own health system. An expert in political violence told the Guardian he sees this as part of the US’s growing acceptance of violence as a way to settle civil disputes. “Now the norms of violence are spreading into the commercial sector,” said Robert Pape, director of the University of Chicago’s project on security and threats. “That’s what I saw when I saw this.” Although the motive for the killing is unknown, it has not stopped rampant speculation that there was an obvious candidate – Thompson’s work in corporate health insurance. That speculation was only furthered by the discovery of shell casings scrawled with the words “deny”, “depose” and “defend” in permanent marker. “What I think we’re really experiencing as a country is the erosion against norms,” said Pape, with the little sympathy among the “body politic” expressed in social media as one more example. “That means, basically, seeing violence as the more normal tool, or acceptable tool, to resolve what should be straightforward civil disputes resolved in nonviolent ways.” Thompson’s killing also laid bare the threat that healthcare executives face in a season of American violence – from insurers to pharma to hospitals . “It doesn’t seem paranoid to worry that someone who’s had services denied that they may believe are important might be in an emotionally unstable state and could take some action,” Michael Sherman, former chief medical officer at Point32Health, told Stat , a health industry publication. “The most likely targets would be the chief medical officer ... or the CEO.” Comments online did not single out Thompson, a 50-year-old licensed accountant who reportedly kept a low profile . Instead, they were targeted at an industry often seen as a despised fact of life in America. Comments laced “jokes” with the sting of denial, delay, debt and impenetrable bureaucracy, all ubiquitous and reviled experiences for the throngs of Americans who are now or have been insured through a private company. Another comment: “Does he have a history of shootings? Denied coverage.” Ranked by size, UnitedHealth Group is one of the biggest companies in the world. Measured by its market capitalization of $539bn it tops household names such as Mastercard and ExxonMobil. The company is one of the biggest private insurers in the nation, providing health coverage to more than 50 million Americans spanning employer insurance all the way to the elderly through Medicare Advantage. Thompson ran the insurance division of the company as a reportedly longtime employee who kept a low profile. With an enormous footprint, it is also the subject of near constant scrutiny. Thompson himself was part of an investigation into insider trading at the company. Early this year, after the Department of Justice began an inquiry into monopolistic practices, executives at United sold $101m in stocks, including Thompson, who sold $15m, before the public became aware of the investigation, according to Crain’s New York Business . Witty was hauled in for congressional testimony over a cyber-attack in February that caused severe disruptions across the healthcare industry. UnitedHealthcare has been criticized as denying care to vulnerable patients . While security executives for leading Fortune 500 companies gathered on Wednesday, others marveled in public that Thompson was unaccompanied on his way to the annual investor conference. Michael Julian, CEO of MPS Security & Protection, told Axios that he “was shocked the guy didn’t have a protective detail”, implying that a head of an American healthcare giant would be an obvious target for the potentially aggrieved. “Whether this technically will fit the pigeonhole of political violence or not, it obviously will be an important issue,” said Pape, whose recent study showed a dramatic increase in instances of violent threats against both Democrats and Republicans since about 2017, the beginning of the first Trump term. “But it also misses the bigger picture of what’s been happening in our country.”Stocks closed higher on Wall Street ahead of the Christmas holiday, led by gains in Big Tech stocks. The S&P 500 added 1.1% Tuesday. Trading closed early ahead of the holiday. Tech companies including Apple, Amazon and chip company Broadcom helped pull the market higher. The Dow Jones Industrial Average rose 0.9%, and the Nasdaq composite climbed 1.3%. American Airlines shook off an early loss and ended mostly higher after the airline briefly grounded flights nationwide due to a technical issue. Treasury yields held steady in the bond market. On Tuesday: Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
iPhone 15 available on Flipkart at Rs 58,999 with discounts of up to Rs 9,000 through bank and exchange offers. The iPhone 15 Plus is listed at Rs 63,999 with an additional Rs 52,000 exchange value. For those with a higher budget, the iPhone 16 is available at Rs 72,500 with better performance and new features. Flipkart sale: If you are looking for an upgrade to an iPhone 15 this New Year, this can be the best time to do so. E-commerce platform Flipkart is offering a great discount on the last-generation vanilla trim. While you miss out on the Apple Intelligence features, you will get a good package with slew of new features including the Dynamic Island, Type-C and better camera along with new fresh colours. The iPhone 15 can currently be bought under Rs 50,000 including the bank offers, exchange offers. Here’s how the deal looks like: iPhone 15 price in India, offers and more: iPhone 15 is currently listed at Rs 58,999 for the base 128GB variant on Flipkart. The customers can get Rs 1,000 instant discount on using select cards or 5 percent unlimited discount on using Flipkart Axis Bank cards. Additionally, the customers will get up to Rs 8,000 additional off on exchange of their old device (depending on the model and condition). The customers can also opt-in for the no-cost EMI options on the select bank cards. Also read: Received call from RBI about bank account blocking? Govt says it’s fake The customers who want bigger screens or battery backup can consider the iPhone 15 Plus. The device is available on Flipkart at Rs 63,999. The customers can get Rs 1,000 instant discount along with up to Rs 52,000 exchange value on the older devices. Should you buy an iPhone 15? The iPhone 15 comes with great updates over the iPhone 14 including an A16 Bionic chipset, up to 26 hours of video playback, Dynamic Island, Type-C port and 48+12MP camera. However, the display remains largely the same with a 6.1-inch OLED panel with a 60hz refresh rate. The customers can get new colours. But if budget is not an issue, you can definitely consider the iPhone 16 as it offers new design, better performance, Apple Intelligence features and even better camera. The iPhone 16 is currently available at Rs 72,500 with all the bank offers on Vijay Sales. Ashish Singh is the Chief Copy Editor at Digit. Previously, he worked as a Senior Sub-Editor with Jagran English from 2022, and has been a journalist since 2020, with experience at Times Internet. Ashish specializes in Technology. In his free time, you can find him exploring new gadgets, gaming, and discovering new places. View Full Profile
Trinity Bank, N.A. (OTCMKTS:TYBT) Short Interest Update